Alector is a clinical-stage biopharmaceutical company that develops therapies for the treatment of neurodegenerative diseases. It offers AL001, a regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders, including frontotemporal dementia (FTD), Alzheimer’s disease, and Parkinson’s disease.
|HQ||South San Francisco, CA, US||Map|
Net income (Q2, 2020)
EBIT (Q2, 2020)
Market capitalization (14-Jan-2021)
Closing stock price (14-Jan-2021)
|USD||Q1, 2018||Q2, 2018||Q3, 2018||Q1, 2019||Q2, 2019||Q3, 2019||Q1, 2020||Q2, 2020|
Depreciation and Amortization
Cash From Operating Activities
|Company Name||Date||Deal Size|
Alector revenue breakdown by business segment: 100.0% from Collaboration
When was Alector founded?
Alector was founded in 2013.
Who are Alector key executives?
Alector's key executives are Arnon Rosenthal, Spencer LIang and Shehnaaz Suliman.
How many employees does Alector have?
Alector has 126 employees.
What is Alector revenue?
Latest Alector annual revenue is $21.2 m.
What is Alector revenue per employee?
Latest Alector revenue per employee is $168.4 k.
Who are Alector competitors?
Competitors of Alector include Verge Genomics, Encoded Therapeutics and NKMax.
Where is Alector headquarters?
Alector headquarters is located at 131 Oyster Point Blvd #600, South San Francisco.
Where are Alector offices?
Alector has offices in South San Francisco and Milpitas.
How many offices does Alector have?
Alector has 2 offices.
Receive alerts for 300+ data fields across thousands of companies